» Articles » PMID: 34064046

Methylation Patterns of , and Are Accompanied with Different Expression Levels in Human Astrocytoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Jun 2
PMID 34064046
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, we investigated genetic and epigenetic changes and protein expression levels of negative regulators of Wnt signaling, , , and as well as glycogen synthase kinase 3 (GSK3β) and β-catenin in 64 human astrocytomas of grades II-IV. Methylation-specific PCR revealed promoter methylation of , , and in 38%, 43%, and 18% of samples, respectively. Grade IV comprised the lowest number of methylated cases and highest of . Evaluation of the immunostaining using H-score was performed for β-catenin, both total and unphosphorylated (active) forms. Additionally, active (pY216) and inactive (pS9) forms of GSK3β protein were also analyzed. Spearman's correlation confirmed the prevalence of β-catenin's active form (r = 0.634, < 0.001) in astrocytoma tumor cells. The Wilcoxon test revealed that astrocytoma with higher levels of the active pGSK3β-Y216 form had lower expression levels of its inactive form ( < 0.0001, Z = -5.332). Changes in exon 11 were observed in 44.44% of samples by PCR/RFLP. Astrocytomas with changes of had higher H-score values of total β-catenin compared to the group without genetic changes (t = -2.264, = 0.038). Furthermore, a positive correlation between samples with methylated promoter and the expression of active pGSK3β-Y216 (r = 0.356, = 0.011) was established. Our results emphasize the importance of methylation for the regulation of Wnt signaling. Large deletions of the gene associated with increased β-catenin levels, together with oncogenic effects of both β-catenin and GSK3β, are clearly involved in astrocytoma evolution. Our findings contribute to a better understanding of the etiology of gliomas. Further studies should elucidate the clinical and therapeutic relevance of the observed molecular alterations.

Citing Articles

Expression of Wnt signaling proteins LEF1, β-catenin, GSK3β, DVL1, and N-myc varies across retinoblastoma subtypes and pRb phosphorylation status.

Markovic L, Bukovac A, Varosanec A, Jakovcevic A, Tomas D, Sonicki Z Sci Rep. 2024; 14(1):31725.

PMID: 39738380 PMC: 11685868. DOI: 10.1038/s41598-024-82044-z.


protein expression is reduced in high grade astrocytomas which is not caused by the methylation of its promoter.

Kafka A, Pecina-Slaus N, Drmic D, Bukovac A, Njiric N, Zarkovic K Front Mol Neurosci. 2024; 17:1398872.

PMID: 38993819 PMC: 11236799. DOI: 10.3389/fnmol.2024.1398872.


Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment.

Pecina-Slaus N, Anicic S, Bukovac A, Kafka A Int J Mol Sci. 2023; 24(7).

PMID: 37047705 PMC: 10095594. DOI: 10.3390/ijms24076733.


High CBX8 Expression Leads to Poor Prognosis in Laryngeal Squamous Cell Carcinoma by Inducing EMT by Activating the Wnt/β-Catenin Signaling Pathway.

Meng Q, Li L, Wang L Front Oncol. 2022; 12:881262.

PMID: 35814427 PMC: 9259798. DOI: 10.3389/fonc.2022.881262.

References
1.
Yue W, Sun Q, Dacic S, Landreneau R, Siegfried J, Yu J . Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis. 2007; 29(1):84-92. DOI: 10.1093/carcin/bgm267. View

2.
Watany M, Badawi R, Elkhalawany W, Abd-Elsalam S . Study of Dickkopf-1 (DKK-1) Gene Expression in Hepatocellular Carcinoma Patients. J Clin Diagn Res. 2017; 11(2):OC32-OC34. PMC: 5376795. DOI: 10.7860/JCDR/2017/23095.9450. View

3.
Gotze S, Wolter M, Reifenberger G, Muller O, Sievers S . Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer. 2009; 126(11):2584-93. DOI: 10.1002/ijc.24981. View

4.
Nikuseva-Martic T, Beros V, Pecina-Slaus N, Pecina H, Bulic-Jakus F . Genetic changes of CDH1, APC, and CTNNB1 found in human brain tumors. Pathol Res Pract. 2007; 203(11):779-87. DOI: 10.1016/j.prp.2007.07.009. View

5.
Katoh M, Katoh M . Molecular genetics and targeted therapy of WNT-related human diseases (Review). Int J Mol Med. 2017; 40(3):587-606. PMC: 5547940. DOI: 10.3892/ijmm.2017.3071. View